At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 25 enrolled
Drug / intervention
Interleukin-2 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial of Low-Dose Interleukin-2 (IL-2) Added to Extra-Corporeal Photopheresis for Steroid-Refractory Chronic Graft-versus-Host-Disease
In Brief
A Phase 2 clinical trial evaluating Extracorporeal Photopheresis (ECP) and Interleukin-2 for Chronic Graft-versus-host-disease. Completed, enrolled 25 participants across 1 site.
Detailed Summary
This research study is evaluating a combination of a therapy called Extra-corporeal Photopheresis (ECP) with a drug called Interleukin-2 (IL-2) as a possible treatment for chronic graft-versus-host-disease (GVHD) following allogeneic stem cell transplant.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Graft-versus-host-disease
CountriesUnited States
CollaboratorsPrometheus Laboratories
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJan 2015
Enrollment StartFeb 2015
Primary CompletionAug 2017
Study CompletionSep 2025
TodayJul 2026
First PostedJan 19, 2015
Enrollment StartFeb 1, 2015
Primary CompletionAug 1, 2017
Study CompletionSep 1, 2025
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 11.5 years ago
Interventions
Extracorporeal Photopheresis (ECP)procedure
Participants receive ECP treatment twice a week for 16 weeks
Interleukin-2drug
Participants receive daily IL-2 injections starting Week 8 of study and ending at Week 16